Press Room

    Back

    Press Release - May 07, 2014

    Sernova Announces Appointment of Nick Borrelly to Corporate Development Role


    Seasoned biopharma executive brings corporate development expertise to Sernova

    Source: Sernova Corp FOR RELEASE May 7th, 2014, 6:00 a.m. EDT

    LONDON, ONTARIO--(Marketwire – May 7th, 2014) - Sernova Corp. (TSX-V: SVA) is pleased to announce that Mr. Nick Borrelly is joining Sernova in a consultant corporate development role. Mr. Borrelly has over 25 years’ experience in corporate/business development as well as marketing and sales in the pharmaceutical (Ciba-Geigy, Novartis and Sanofi-Aventis) and biopharma industries. As President of Camargue Consulting, he specializes in development, evaluation and in-licensing of technologies, initiation of strategic alliances with multi-national corporate partners, and leading sales and marketing teams for commercial stage products.

    “Nick’s extensive corporate development network and partnering expertise will be invaluable to creating significant shareholder value through attracting strong commercialization partners for our products. As Sernova is now exploring additional clinical applications of the Cell Pouch(TM), establishing corporate partners to help accelerate development has become an important part of our corporate strategy forward”, stated Dr. Philip Toleikis, Sernova’s President and CEO.

    Mr. Borrelly said, “I am excited to work with Sernova’s CEO, Dr. Philip Toleikis, and his team to fully implement the strategic vision for its disruptive technologies for the cell-based treatment of chronic diseases.”

    Nick’s past roles include Manager, Business Development - Licensing & Acquisitions with Sanofi Aventis Pharma Canada; Vice President, Business Development for MNLpharma (U.K.) Ltd.; and Vice President, Business Development for CV Technologies/Afexa Life Sciences Inc. As a Director with Nucleus BioScience Inc., he coordinated its amalgamation with Stratos BioSciences Inc. and Brightwave Technologies Inc. to create SNB Capital Corp., which subsequently took the biotherapeutics company Protox Therapeutics Inc. (now Sophiris Bio Inc; NASDAQ: SPHS) public in 2004. Nick is currently a member of the Board of Directors of Eternity Healthcare (OTCBB: ETAH), and Auxellence Health Corporation (CSE: AID).

    About Sernova Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary local immune protection technologies.

    For further information contact:

    Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com info@sernova.com www.sernova.com

    Ray Matthews & Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 Tel: (604) 818-7778 www.raymatthews.ca

    Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →